Protocol of the randomized controlled trial of electronic Patient-Reported Outcome Monitoring with Integrated hospital-community pharmaciSt Engagement for diverse outpatient anticancer chemotherapy: the PRO-MISE trial.
Itsuki Osawa, Tohru Takebe, Shuhei Saito, Michiko Yamazaki, Tomoya Saika, Hideyuki Ohzawa, Shunsuke Yui, Hiroki Yamaguchi, Yasushi Imai, Takuhiro Yamaguchi, Shunya Ikeda
Int J Clin Oncol 10.1007/s10147-026-03248-z
摘要
摘要
BACKGROUND: Patients receiving outpatient systemic anticancer therapy may develop symptoms between visits. Clinicians may under-recognize these symptoms, delaying supportive care and compromising health-related quality of life (HRQoL). We will test whether weekly smartphone-based electronic Patient-Reported Outcome (ePRO) monitoring linked to community-pharmacist review and structured communication with treating institutions improves HRQoL across diverse cancers. METHODS: This multicenter, pragmatic, open-label, randomized controlled trial will allocate 880 adults 1:1 to pharmacist-linked ePRO monitoring or usual care for 24 weeks. Intervention participants report 16 prespecified PRO-CTCAE symptoms weekly. Community pharmacists review responses, contact and counsel patients when clinically indicated, and escalate urgent concerns directly to the treating institution. All responses are also available to the treating institution. The primary outcome is three-category change (improved/stable/worsened) in the EORTC QLQ-C30 Summary Score from baseline to week 12. Secondary outcomes include week-24 and domain-specific HRQoL, survival, unplanned treatment discontinuation, hospitalization, emergency department visits, and pharmacist process measures. The sample provides 80% power to detect a proportional odds ratio of 1.50, assuming 74% week-12 questionnaire completion. The study was approved by the Institutional Review Board of the International University of Health and Welfare (ID: 26-CC-001). DISCUSSION: The PRO-MISE trial will evaluate a pharmacist-linked ePRO workflow across diverse outpatient cancer populations. If effective, it could support Japanese practice, where community pharmacists maintain inter-visit contact; implementation elsewhere would require adaptation to local pharmacy roles and information-sharing pathways. The trial will also quantify patient engagement and pharmacist follow-up across routine care settings. TRIAL REGISTRATION: UMIN-CTR ID, UMIN000061721.
KM 提取结果
0 个 Figure · 0 个 KM 面板